Cargando…
Engineered SARS-CoV-2 receptor binding domain improves immunogenicity in mice and elicits protective immunity in hamsters
Global containment of COVID-19 still requires accessible and affordable vaccines for low- and middle-income countries (LMICs).(1) Recently approved vaccines provide needed interventions, albeit at prices that may limit their global access.(2) Subunit vaccines based on recombinant proteins are suited...
Ejemplares similares
-
Engineered SARS-CoV-2 receptor binding domain improves manufacturability in yeast and immunogenicity in mice
por: Dalvie, Neil C., et al.
Publicado: (2021) -
A modular protein subunit vaccine candidate produced in yeast confers protection against SARS-CoV-2 in non-human primates
por: Dalvie, Neil C., et al.
Publicado: (2021) -
SARS-CoV-2 receptor binding domain displayed on HBsAg virus–like particles elicits protective immunity in macaques
por: Dalvie, Neil C., et al.
Publicado: (2022) -
Antigen-adjuvant interactions, stability, and immunogenicity profiles of a SARS-CoV-2 receptor-binding domain (RBD) antigen formulated with aluminum salt and CpG adjuvants
por: Bajoria, Sakshi, et al.
Publicado: (2022) -
Intranasal vaccination with lipid-conjugated immunogens promotes antigen transmucosal uptake to drive mucosal and systemic immunity
por: Hartwell, Brittany L., et al.
Publicado: (2022)